Research Projects & Grants

For Profit Organization

  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (12/2024 - 12/2025) Status: Approved

Internal

  • Investigator initiated: Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in breast and gynecologic-oncology patients: A prospective, randomized, open-label study, Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (02/2024 - 01/2025) Status: Completed
  • Predictors of hypomagnesemia with denosumab in patients with metastatic bone disease from solid malignancies: A single-institution retrospective study, Role: Investigator, LLU Dept. of Pharmacy Practice, (11/2023) Status: Approved
  • Bicalutamide plus leuprolide versus degarelix plus leuprolide as androgen deprivation therapy for patients with advanced or metastatic prostate cancer: A retrospective cohort study assessing incidence of tumor flare and cost-differences between each regimen, Role: Investigator, LLU Dept. of Pharmacy Practice, (11/2022 - 01/2024) Status: Completed
  • Investigator Initiated: A Retrospective chart review of patients treated with immune checkpoint inhibitors (ICI) to evaluate severe and fatal adverse events in the emergency department, Role: PI, LLU Dept. of Pharmacy Practice, (07/2021 - 10/2024) Status: Completed
  • Investigator Initiated: The bone-targeting agents and the need for electrolyte monitoring in cancer patients: A retrospective cohort study of cancer patients treated between January 1,2014 to June 24, 2020, Role: PI, LLU Dept. of Pharmacy Practice, (07/2020 - 09/2024) Status: Completed
  • Prevention of Taxol hypersensitivity reactions: Oral dexamethasone given night before and morning of Taxol infusion versus short-course intravenous dexamethasone infusion given 30 minutes prior to Taxol infusion (retrospective review), Role: PI, LLU Dept. of Pharmacy Practice, (09/2016 - 09/2017) Status: Completed
  • Medication reconciliation in an ambulatory cancer center --impact of the oncology pharmacist, Role: PI, LLU Dept. of Pharmacy Practice, (07/2016 - 07/2017) Status: Completed
  • Safety and efficacy of pegfilgrastim when given less than 14-days before next chemotherapy cycle: a retrospective review of 14 days regimens containing 5-fluorouracil continuous infusions, Role: PI, LLU Dept. of Pharmacy Practice, (07/2016 - 07/2017) Status: Completed
  • Lymphocytosis in patients receiving outpatient interleukin-2 therapy, Role: Investigator, LLU Cancer Institute, (11/2011 - 11/2012) Status: Completed
  • Risk Factors of Hypomagnesemia in Patients with Bone Metastases from Solid Malignancies Treated with Zoledronic Acid: A Single-institution Retrospective Study, Role: PI, LLU Dept. of Pharmacy Practice, (10/2024) Status: Approved
  • Cost analysis of subcutaneous daratumumab compared to intravenous daratumumab in multiple myeloma patients: A retrospective chart review, Role: PI, LLU Dept. of Pharmacy Practice, (11/2024) Status: Approved